Arthritis Research Canada responding to COVID-19
In light of the recent developments with the COVID-19 outbreak and the changing recommendations from the governments of BC and Canada, Arthritis Research Canada is carefully monitoring the information and implementing a number of protocols to ensure our volunteers, research participants, students, and staff are informed and protected according to the latest reports. We are encouraging everyone to follow the advice being provided so that we may help prevent the spread of the virus in our communities and country. While we are concerned for all people, we are particularly so for those with autoimmune diseases and/or those who are immunosuppressed. We are working to provide up-to-date answers to your questions and will be updating this page regularly.
COVID-19 Research Videos
Dr. Diane Lacaille - COVID-19 Global Rheumatology Alliance
Dr. Diane Lacaille is the Canadian lead on a worldwide alliance to collect information on rheumatology patients with COVID-19. This study can provide important insights on how the COVID-19 infection impacts our patients, and how arthritis medications may add to the risk of infection.
Dr. Mary De Vera - UNIFIED COVID-19 Study
The UNIFIED Study addresses the impact of COVID-19 on medication use and mental health for people with arthritis. This study seeks to better understand the experiences of individuals with rheumatic diseases and immunosuppressive conditions during the COVID-19 pandemic.
Dr. Catherine Backman - Arthritis Research Adapted to Understand Impact of COVID-19
Dr. Catherine Backman and her team’s study to explore the health benefits of everyday activities for people with inflammatory arthritis has been adapted in response to COVID-19. A newly added component will assess the effects of self-isolation and staying at home. By better understanding how arthritis and social isolation affect the daily activities that support the health and well-being of people with and without inflammatory arthritis, this research will help improve arthritis self-management studies, rehabilitation programs and public heath recommendations.
Jenny Leese, MA, PhD Candidate - Studying the Impact of COVID-19 on Physical Activity & Self-Care
Jenny Leese, Arthritis Research Canada trainee and member of the research team led by Senior Research Scientist, Dr. Linda Li – shares an update about two current rheumatoid arthritis studies: OPAM-IA and OPERAS, and how they have been adapted in response to COVID-19.
Both studies will examine how are COVID-19 and B.C’s pandemic response (e.g. social distance and stay-at-home orders) affecting physical activity and self-care management for people with rheumatoid arthritis. Additionally, the team will explore mental and physical health, diet, finances, and access to essential medications. By better understanding the impacts of COVID-19, our research can help improve self-care strategies and rehabilitation services for arthritis management.
Dr. Linda Li - How Arthritis Research on Active Self-Management is Adapting to COVID-19
Dr. Linda Li’s research on active self-management of arthritis has been adapted to address the impact of COVID-19. The OPERAS study tracks the physical health and self-management of people with RA and will be monitoring changes in patients’ health and physical activity during and after COVID-19. This new information will help researchers better understand and improve care for people with rheumatoid arthritis.
Learn more about the OPERAS study:
Frequently Asked Questions [May 14, 2020]
Remdesivir Update (taken from FDA News Release, May 1, 2020)
The U.S. Food and Drug Administration (known best as the FDA) issued an emergency use authorization for the investigational antiviral drug remdesivir (given intravenously) for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. The FDA defined severe disease as patients with low blood oxygen levels or needing oxygen therapy or more intensive breathing support such as a mechanical ventilator.
The FDA determined that it is reasonable to believe that remdesivir may be effective in treating COVID-19, and that, given there are no adequate, approved, or available alternative treatments, the known and potential benefits to treat this serious or life-threatening virus currently outweigh the known and potential risks of the drug’s use.
Thus, remdesivir is not absolutely proven to work as yet, but the FDA considers it the front runner to have benefit in treating the virus. This is good news for those with the most severe COVID-19 cases – it may well make a big difference.
Are there concerns about taking anti-inflammatory medications?
• In light of observations that patients taking ibuprofen may have more severe respiratory illness when affected by COVID-19, the WHO had recommended to avoid using ibuprofen to treat symptoms of COVID-19 and to use acetaminophen instead to treat fever or headaches. Since then, the WHO has retracted their statement due to lack of good quality evidence. Health Canada has followed WHO’s advice. Since the issue is not clear, we recommend avoiding the use of non-steroidal anti-inflammatory drugs, also called NSAIDs, if not necessary to control pain. We recommend trying acetaminophen on a regular schedule up to the maximum recommended dose of 3 grams per day to control arthritis pain, and consider using NSAIDs only if there are no other options for pain control.
• Examples of non-steroidal anti-inflammatory medications include ibuprofen (Advil), naproxen (Aleve), diclofenac (Voltaren), indomethacin (Indocid), celecoxib (Celebrex), meloxicam (Mobicox) and Naprosyn. If you are unsure if your medication is an NSAID, contact your pharmacist.
• Please click the links below for recommendations from:
What is known about the rate and severity of infection in patients with rheumatologic disease, especially those patients taking prednisone, DMARDs (Disease Modifying Anti-Rheumatic Drugs) such as hydroxychloroquine (Plaquenil), sulfasalazine, methotrexate and leflunomide (Arava), biologics, or immunosuppressive agents?
Currently, there is no specific data on SARS-CoV-2 in patients with rheumatologic disease or immunosuppression. However, the medications listed do suppress the immune system and therefore increase the risk of having a more severe infection if patients come in contact with the virus. Therefore, people on these medications are considered at high risk and should take extra precautions to avoid contact and should seek medical attention if they have any symptoms, following the local directives for testing and accessing health care if symptoms.
Should patients who are taking prednisone, DMARDs (Disease Modifying AntiRheumatic Drugs) such as hydroxychloroquine (Plaquenil), sulfasalazine, methotrexate and leflunomide (Arava), biologics, or other drugs for their rheumatic diseases stop them?
• It is not recommended for people to stop their DMARD medications if they have no symptoms of COVID-19 as uncontrolled inflammation due to the arthritis can be harmful for the body’s response to the virus.
• Stopping prednisone abruptly is also dangerous to one’s health, as the body’s own production of cortisol is suppressed.
• It is unclear if people should interrupt therapy during episodes of infection (i.e. if symptomatic or positive for COVID-19), as some of the severe manifestations of COVID-19 are due to the body’s immune response to the virus and, therefore, in theory some medications used to treat auto-immune diseases might be helpful. However, good evidence is still lacking. Patients should talk to their rheumatologist or prescribing doctor prior to discontinuing any of their medications. This is a complex decision based on the specific medication used, assessment of risk factors, other chronic diseases, and of the specific situation.
• There is some suggestion that hydroxychloroquine (Plaquenil), chloroquine (not available in North America), and anti-IL-6 drugs tocilizumab (Actemra) and sarilumab (Kevzara) may benefit those hospitalized with severe COVID-19 infection. This is not proven.
Are any pharmacologic measures (prophylactic or therapeutic) recommended?
There are currently no prophylactic or therapeutic measures beyond supportive care recommended for this virus. Testing of potential therapies is underway in many countries, and the work to develop a vaccine is also moving forward. However, it is unclear when these will be available.
What can patients do to protect themselves against contracting this disease?
• Patients who are on DMARDs, prednisone, or biologics should avoid contact with people who are sick with COVID-19 or who are at high risk (e.g. returning from travel) and should limit the number of visitors to their homes.
• The BCCDC and other sources have underscored the importance of hand hygiene, with frequent and effective hand washing (for 20 seconds) with soap and water.
• One can use alcohol-based hand sanitizer if soap and water are not available.
• As important as hand washing is, avoiding to touch one’s face, mouth and eyes (i.e. all mucous membranes) and thoroughly washing hands before, if necessary to do so.
• Social distancing (i.e. staying at least 2 metres away from others), working from home, and avoiding public spaces or public transit, etc., are all recommended measures for reducing the risk of contact with cases in the community. The main mode of transmission is through droplets from an infected person that are spread through coughing and sneezing.
• Recommendations about wearing masks have changed since the onset of the pandemic and vary according to region. Although BC is not mandating it, Health Canada and the US Center for Disease Control (CDC) recommend that people wear masks when outside of the house, especially in more crowded environments, such as in public transit or when doing errands. For this purpose, disposable surgical masks, or home made masks that fit snugly from the bridge of the nose to under the chin, suffice. This is primarily to prevent the spread of the virus from people who have no symptoms and may not be aware they are carrying the virus. However, it also protects the person wearing the mask to some extent. If in contact with a person with known COVID19, a special kind of mask, called an N95 mask, is necessary for better protection.
• It is recommended to frequently wash and commonly touched surfaces such as: tables, doorknobs, light switches, handles, desks, toilets, faucets, sinks, steering wheels, keys with household cleaners. Washing with household cleaners will remove the virus from surfaces. Using disinfectants after washing, gives the additional protection of killing viruses. Alcohol based products (> 70%), diluted bleach (1:9 dilution with water – never mix bleach with other cleaning products) and other EPA-registered household disinfectants can be used. Coronaviruses are susceptible to soap and detergents. Further information is available on the BCCDC website.
• Washing clothing or linen items with the highest heat appropriate for the item and using the dryer is also an effective means of cleaning cloth items. The virus is susceptible to heat.
• Do not share food, drinks, utensils, and do not eat from buffets, etc.
• Do not shake hands.
• When coughing or sneezing, cough or sneeze into a tissue or the bend of your arm, not your hand. Dispose of any tissues you have used as soon as possible in a lined waste basket and wash your hands afterwards.
What else can patients and their providers do?
• Patients should make sure they have received all appropriate vaccinations, including seasonal influenza, pneumonia, pertussis, and shingles vaccines. These will not prevent COVID-19, but will protect against those diseases, which if you had them (e.g. influenza) would likely make you more susceptible to more severe COVID-19 infection and vice versa.
• In addition, patients should keep ample stocks (e.g. one-month supply) of necessary medications on hand in case they are prevented from refilling prescriptions in a timely manner.
Research Participation Opportunities
COVID-19 Global Rheumatology Alliance
Arthritis Research Canada/Arthrite-recherche Canada is collaborating with the COVID-19 Global Rheumatology Alliance on an international initiative collecting information on rheumatology patients with COVID-19 from around the world. By gathering data specific to rheumatology patients, the Alliance will gain important insights on how COVID-19 impacts rheumatology patients, and more specifically, how autoimmune diseases and immunosuppressive medications influence the risk of infection and the outcomes of COVID-19.
A separate initiative by the COVID-19 Global Rheumatology Alliance, is collecting information from adults (and parents of children) with rheumatic diseases to gain a better understanding of how the COVID-19 pandemic is impacting people living with rheumatic diseases. If you would like to participate, please visit https://rheum-covid.org/patient-survey/
UNIFIED COVID-19 Study
This study seeks to better understand the experiences of individuals with rheumatic diseases and immunosuppressive conditions during the COVID-19 pandemic.
Empowering active self-management of arthritis: Raising the bar with OPERAS (an On-demand Program to EmpoweR Active Self-management)
This project will investigate whether an online intervention app can improve a patient’s ability to manage his or her rheumatoid arthritis. The “On-demand Program to EmpoweR Active Self-management” (OPERAS) links to a Fitbit Flex and combines disease activity monitoring and physical activity counselling.
Arthritis Wellness Conversation on COVID-19
Arthritis Wellness Conversations - Navigating COVID-19 When You Have Arthritis
A first Arthritis Wellness Conversation hosted by Chronic Wellness Radio host, Sandra Sova. Members of our Patient Advisory Board share their personal stories and tips on coping with COVID-19. Joined by our Associate Scientific Director, Diane Lacaille to provide her expert insights.